Elvitegravir + Elvitegravir%2C Cobicistat%2C Emtricitabine%2C And Tenofovir Alafenamide Interaction
Unknowninteraction on record
Description
Elvitegravir is a modest inducer of CYP2C9 and may decrease the plasma concentrations of CYP2C9 substrates. 7.3 Potential for Other Drugs to Affect One or More Components of GENVOYA Elvitegravir and cobicistat, components of GENVOYA, are metabolized by CYP3A. Drugs that induce CYP3A activity are expected to increase the clearance of elvitegravir and cobicistat, resulting in decreased plasma concentration of cobicistat, elvitegravir, and TAF, which may lead to loss of therapeutic effect of GENVOYA and development of resistance (see Table 5 ).
Source: FDA drug label - elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide